This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 5,207 trials Clear all
Filter by:

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Smoking Cessation
    Smoking Cessation
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Zonisamide, Drug: Bupropion, Other: Halo G6 e-cigarette

Eligibility
  • Ages: 21 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Zonisamide, Drug: Bupropion, Other: Halo G6 e-cigarette

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Rose Research Center, Charlotte, North Carolina, United States

Brief Summary

This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline data on use of combustible cigarettes. Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in addition to continued use of the G6. At each visit, participants will receive enough zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6 and combination zonisamide and bupropion use will continue until the participant returns for the End-of-Study visit (V7).

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Danderyd Hospital, Danderyd, Sweden

Brief Summary

There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness. Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID-19. However, data is limited to small studies and case series on severely ill patients. The proposed study assesses the safety and efficacy earlier in the course of illness, in slightly less severe patients with the possibility of detecting less severe adverse events and the potential for early treatment to hinder the development of severe disease. Plasma is collected from consenting donors who have recovered from SARS-CoV-2.

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Amyotrophic Lateral Sclerosis
    Amyotrophic Lateral Sclerosis
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: ALZT-OP1a (cromolyn)

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ALZT-OP1a (cromolyn)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UCSD Altman Clinical and Translational Research Institute, La Jolla, California, United States

Brief Summary

This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

  • Status Recruiting
    Recruiting
  • Condition Atopic Dermatitis
    Atopic Dermatitis
  • Phase Phase 2
    Phase 2
INTERVENTION

Biological: FB825, Other: Placebo

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: FB825, Other: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Zenith Research, Beverly Hills, California, United States

Brief Summary

The study aims to evaluate the efficacy, improvement from baseline in Eczema Area and Severity Index (EASI) score, of multiple intravenous (IV) doses of FB825 in subjects with atopic dermatitis

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Chronic Hepatitis B
    Chronic Hepatitis B
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beijing Ditan Hospital, Capital Medical University, Beijing, China

Brief Summary

Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon alfa-2b injection, with nucleos(t)ide (NAs), tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B, who has previously treated with nucleos(t)ides and who are treatment naïve.

Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Allergic Conjunctivitis, Allergic Rhinitis
    Allergic Conjunctivitis, Allergic Rhinitis
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Eye Drops, Solution in Single-Dose Container

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Eye Drops, Solution in Single-Dose Container

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Vienna Challenge Chamber, Vienna, Austria

Brief Summary

Allergic conjunctivitis is one of the most common comorbidities of allergic diseases, especially of allergic rhinitis. Rhinoconjunctivitis is an allergic condition of the nasal mucosa and the eyes. Conjunctivitis is triggered by hypersensitivity to certain pollens and other airborne allergens and causes several symptoms such as reddened eyes, itchy eyes and can cause watery eyes and a scratchy feeling in the eye. Tacrolimus is a well-known immunosuppressiv active substance which is hardly soluble in water. Within Tacrosolv, Tacrolimus is completely dissolves in aqueous solution. The effectiveness of Tacrosolv will be tested for treatment of allergic conjunctivitis. Allergic subjects will be treated with aqueous formulation of tacrolimus 'Tacrosolv 50 micrograms per milliliter, eye drops' for 8 days. On day 1 and day 8 allergic patients will be challenged with grass pollen for a period of 4 hours and subjective allergic symptoms will be assessed.

Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Coronavirus Infection, Covid-19, SARS-CoV-2
    Coronavirus Infection, Covid-19, SARS-CoV-2
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Ensifentrine Dose 1, Drug: Placebo pMDI

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Ensifentrine Dose 1, Drug: Placebo pMDI

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to COVID-19 infection.

Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: AVIGAN, Drug: Placebo Comparator

Eligibility
  • Ages: 21 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: AVIGAN, Drug: Placebo Comparator

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait

Brief Summary

This is a prospective, interventional, multi-centre, phase III, randomized, double blind, placebo-controlled, parallel design trial to evaluate the efficacy, safety and tolerability of favipiravir as adjunct ('add on') to supportive care, in comparison to placebo with supportive care, in the acute treatment of patients who have tested positive for SARS-CoV-2 and presenting with moderate to severe COVID-19. This study will be conducted in two parts; Stage I - Main study and Stage II - Extended Follow up.

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Pruritus, Cholestasis, Kidney Failure
    Pruritus, Cholestasis, Kidney Failure
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: EP547, Drug: Placebo

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: EP547, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CMAX Clinical Research, Adelaide, South Australia, Australia

Brief Summary

This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.

SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Early Parkinson's Disease
    Early Parkinson's Disease
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: PT320 2.0mg Placebo, Drug: PT320 2.0 mg, Drug: PT320 2.5 mg

Eligibility
  • Ages: 40 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: PT320 2.0mg Placebo, Drug: PT320 2.0 mg, Drug: PT320 2.5 mg

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

Brief Summary

This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320, Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).